IMUX
HealthcareImmunic, Inc.
$0.64
+$0.05 (+9.26%)
Jan 5, 2026
Price History (1Y)
Analysis
Immunic, Inc. is a biotechnology company in the healthcare sector with 90 employees and a market capitalization of $76.65 million. The company operates within the industry of biotechnology. Financially, Immunic, Inc. has reported negative profitability metrics, including gross margin, operating margin, and profit margin all at 0.0%. The company's returns have been substantial losses, with return on equity (ROE) at -398.5% and return on assets (ROA) at -125.1%. From a balance sheet perspective, Immunic, Inc. has cash reserves of $35.13 million and debt of $792,000, resulting in a debt-to-equity ratio of 7.54. Immunic, Inc.'s valuation metrics are notable, with a forward P/E ratio of -1.71 and an EV/EBITDA ratio of -0.34. The company's stock price has ranged from $0.51 to $1.39 over the past year.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Immunic, Inc.
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Visit website →Key Statistics
- Market Cap
- $76.65M
- P/E Ratio
- N/A
- 52-Week High
- $1.39
- 52-Week Low
- $0.51
- Avg Volume
- 1.38M
- Beta
- 1.55
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 90